Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John F Forbes

Showing results (71-80 of 85) with videos related to

Pageof 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2011
Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane studyJudith M Bliss, Lucy S Kilburn, Robert E Coleman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008
Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trialDiana Crivellari, Zhuoxin Sun, Alan S Coates, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2007
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98Alan S Coates, Aparna Keshaviah, Beat Thürlimann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancerMartin R Stockler, Vernon J Harvey, Prudence A Francis, et al.
Journal of Thrombosis and Haemostasis : JTH|July 9, 2021
Remote history of VTE is associated with severe COVID-19 in middle and older age: UK Biobank cohort studyJana J Anderson, Frederick K Ho, Claire L Niedzwiedz, et al.
British Journal of Cancer|April 20, 2016
Adjuvant ovarian function suppression and cognitive function in women with breast cancerKelly-Anne Phillips, Meredith M Regan, Karin Ribi, et al.
Nature Communications|February 3, 2015
Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic valueClare Stirzaker, Elena Zotenko, Jenny Z Song, et al.
Breast Cancer Research and Treatment|November 13, 2012
Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus ConferenceMasakazu Toi, John R Benson, Eric P Winer, et al.
The New England Journal of Medicine|March 5, 2015
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapyHalle C F Moore, Joseph M Unger, Kelly-Anne Phillips, et al.
Trials|April 24, 2015
Preconditioning Shields Against Vascular Events in Surgery (SAVES), a multicentre feasibility trial of preconditioning against adverse events in major vascular surgery: study protocol for a randomised control trialDonagh Healy, Mary Clarke-Moloney, Brendan Gaughan, et al.
Pageof 9

Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2011
Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane studyJudith M Bliss, Lucy S Kilburn, Robert E Coleman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008
Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trialDiana Crivellari, Zhuoxin Sun, Alan S Coates, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2007
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98Alan S Coates, Aparna Keshaviah, Beat Thürlimann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancerMartin R Stockler, Vernon J Harvey, Prudence A Francis, et al.
Journal of Thrombosis and Haemostasis : JTH|July 9, 2021
Remote history of VTE is associated with severe COVID-19 in middle and older age: UK Biobank cohort studyJana J Anderson, Frederick K Ho, Claire L Niedzwiedz, et al.
British Journal of Cancer|April 20, 2016
Adjuvant ovarian function suppression and cognitive function in women with breast cancerKelly-Anne Phillips, Meredith M Regan, Karin Ribi, et al.
Nature Communications|February 3, 2015
Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic valueClare Stirzaker, Elena Zotenko, Jenny Z Song, et al.
Breast Cancer Research and Treatment|November 13, 2012
Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus ConferenceMasakazu Toi, John R Benson, Eric P Winer, et al.
The New England Journal of Medicine|March 5, 2015
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapyHalle C F Moore, Joseph M Unger, Kelly-Anne Phillips, et al.
Trials|April 24, 2015
Preconditioning Shields Against Vascular Events in Surgery (SAVES), a multicentre feasibility trial of preconditioning against adverse events in major vascular surgery: study protocol for a randomised control trialDonagh Healy, Mary Clarke-Moloney, Brendan Gaughan, et al.
Pageof 9